Extrait

Primary Objective: - Evaluate the rate of Atrial Fibrillation (AF) recurrences one month after randomization according to different timings of initiation of dronedarone. Secondary Objective: - Evaluate the rate of AF recurrences two months after randomization. - Assess the safety of the change from amiodarone to dronedarone - Assess dronedarone safety - Explore dronedarone and its active metabolite plasma level (in a subset of countries) - Explore potential Pharmacokinetic (PK) interaction between dronedarone and amiodarone (in a subset of countries)

Critère d'inclusion

• Atrial fibrillation

Pays

• Australia
• Austria
• Estonia
• Finland
• France
• Germany
• Israel
• Italy
• Korea, Republic of
• Mexico
• Netherlands
• Portugal
• Spain
• Switzerland
• Taiwan, Province of China
• United Kingdom

Liens

• ictrp
• nct